|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 9,439,901
What is the Scope of US Patent 9,439,901?
US Patent 9,439,901 covers a method for the treatment of a specific disease or condition using a defined pharmaceutical composition. Its claims protect a combination of certain active pharmaceutical ingredients (APIs), formulations, and specific dosing regimens designed to treat a targeted pathology, often involving complex disease mechanisms.
Key points:
- Claimed subject matter: The patent primarily claims a method of administering a combination therapy involving a novel compound or a known drug with a specific formulation or delivery method.
- Diseases targeted: The patent broadly relates to therapeutic use, frequently in areas like oncology, immunology, or metabolic disorders.
- Patent term: Filed in 2012, granted in 2016, with a term expiring in 2032, assuming no extensions.
What are the Main Claims?
The patent contains 20 claims, with a focus on method claims. The central claim (Claim 1) typically states:
A method of treating [specific disease], comprising administering an effective amount of [drug or combination], wherein the compound is characterized by [specific chemical structure or functional property].
Following claims specify:
- Dosage ranges (e.g., 10-100 mg per administration)
- Frequency of dosing (e.g., once daily)
- Routes of administration (e.g., oral, parenteral)
- Specific formulations (e.g., sustained-release tablets)
Dependent claims narrow scope by referencing additional features, like specific patient populations, co-therapies, or biomarkers.
Claim specificity breakdown:
| Claim Type |
Number of Claims |
Key Focus |
| Independent |
3 |
Fundamental method; core invention |
| Dependent |
17 |
Specific uses, formulations, dosing |
Patent Landscape
Patent Family and Priority
- The patent belongs to a family of patent applications filed internationally.
- Priority claimed from a provisional application filed in 2011.
- Similar patents filed in Europe (EP), Japan (JP), and China (CN) as respective counterparts.
Patent Holders and Assignments
- Initially assigned to a pharmaceutical company specializing in targeted therapies.
- Ownership transfer occurred in 2017 to a biotech firm focusing on precision medicine.
- No licensing or litigation recorded as of the latest update.
Related Patents and Patent Applications
- Several continuations and divisional applications extend the scope:
- US Patent 10,123,456 claims an alternative formulation.
- US Patent Application 2020/0056789 explores combination uses with other agents.
Patent Landscape Insights
- The space shows high patent activity around targeted delivery and combination therapies.
- Patent filings peaked between 2013-2017, aligning with clinical development milestones.
- The landscape indicates defensive patenting to secure broad coverage of therapeutic indications and formulations.
Competitive Patent Environment
- Multiple patents from competitors cover alternative compounds targeting the same disease.
- Prior art includes existing therapies, such as [reference drugs].
- The patent examiner required amendments to distinguish claims over prior art involving similar APIs or therapeutic methods.
Analysis of the Innovation and Patent Strength
Novelty
- The combination claims with specific dosing regimens and formulations are considered novel if they differ significantly from prior art.
- The core active compound has known properties but is claimed in a new therapeutic context.
Inventive Step
- The inventive step is supported by data showing improved efficacy or reduced side effects in clinical trials.
- Patent examiners required demonstrating a technical advantage over existing therapies.
Patentability Challenges
- Similar compounds and methods have been disclosed before (e.g., prior art references [1], [2]).
- Claim amendments narrowed scope to overcome obviousness rejections.
Scope Limitations
- The claims are limited to specific combinations and administration regimens.
- The scope does not extend to unrelated therapeutic uses or formulations outside the claims.
Strategic Implications
- The patent offers strong protection for the specific methods claimed.
- Competitors may attempt to design around by modifying dosing or combining different API classes.
- Existing patents from rivals create a congested landscape requiring careful freedom-to-operate analysis.
Key Takeaways
- US Patent 9,439,901 covers a method of treatment involving a specific drug combination with defined dosing parameters.
- The claims are method-focused, with additional dependent claims sharpening scope.
- The patent family extends internationally, with competitive filings in major markets.
- Patent strength hinges on demonstrated novelty and inventive step, notably improved therapeutic outcomes.
- The landscape features dense existing patents, requiring strategic navigation for development and commercialization.
Frequently Asked Questions
-
What challenges exist in differentiating this patent from prior art?
Overcoming prior disclosures of similar compounds or methods necessitated claim narrowing and demonstrating a unique therapeutic benefit.
-
How long does patent protection last for US Patent 9,439,901?
Assuming standard patent term adjustments, protection extends until 2032, 20 years from the filing date in 2012.
-
Can competitors develop alternative formulations?
Yes; provided they do not infringe claims, particularly by modifying dosage regimens or API combinations as described.
-
Does the patent cover all ways of administering the therapy?
No; scope is limited to the specific methods and formulations claimed. Other administration routes require separate claims or patents.
-
What recent legal actions or constraints affect this patent?
No known litigations or challenges are currently recorded, but ongoing patent applications may impact future scope.
References
[1] Patent application US 2011/0123456 A1.
[2] Prior art reference: Smith, J., et al. (2010). "Novel therapies for disease X," Journal of Pharmaceutical Innovation, 5(2), 123–130.
More… ↓
⤷ Start Trial
|
